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Abstract
Background: Secretory leukoproteinase inhibitor (SLPI) is an important inhibitor of neutrophil
elastase (NE), a proteinase implicated in the pathogenesis of lung diseases such as COPD. SLPI also
has antimicrobial and anti-inflammatory properties, but the concentration of SLPI in lung secretions
in COPD varies inversely with infection and the concentration of NE. A fall in SLPI concentration
is also seen in culture supernatants of respiratory cells exposed to NE, for unknown reasons. We
investigated the hypothesis that SLPI complexed with NE associates with cell membranes in vitro.
Methods: Respiratory epithelial cells were cultured in the presence of SLPI, varying doses of
proteinases over time, and in different experimental conditions. The likely predicted charge of the
complex between SLPI and proteinases was assessed by theoretical molecular modelling.
Results: We observed a rapid, linear decrease in SLPI concentration in culture supernatants with
increasing concentration of NE and cathepsin G, but not with other serine proteinases. The effect
of NE was inhibited fully by a synthetic NE inhibitor only when added at the same time as NE. Direct
contact between NE and SLPI was required for a fall in SLPI concentration. Passive binding to cell
culture plate materials was able to remove a substantial amount of SLPI both with and without NE.
Theoretical molecular modelling of the structure of SLPI in complex with various proteinases
showed a greater positive charge for the complex with NE and cathepsin G than for other
proteinases, such as trypsin and mast cell tryptase, that also bind SLPI but without reducing its
concentration.
Conclusion: These data suggest that NE-mediated decrease in SLPI is a passive, charge-dependent
phenomenon in vitro, which may correlate with changes observed in vivo.
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Background
SLPI is an efficient inhibitor of NE and other serine protei-
nases[1,2] and is found in high concentrations in secre-
tions such as respiratory mucus[3]. In vitro it has
antibacterial [4-6] and antifungal[7] properties and has
been shown to prevent viral infection[8,9]. In addition it
has anti-inflammatory properties distinct from inhibition
of extracellular NE, that are potentially important in host
defence and auto-immune conditions [10-14]. These
properties suggest that SLPI may be important in diseases
such as bronchiectasis and COPD that are characterized
by neutrophilic inflammation and infection. SLPI should
be protective in these conditions, and indeed patients
with chronic bronchitis (CB) have a higher concentration
of SLPI in lung secretions than healthy controls[15], prob-
ably because of submucosal gland hypertrophy and
increased serous cell secretion. However the amount of
SLPI found in the sputum of patients with CB and bron-
chiectasis decreased during exacerbations [16-18] and
increased again in the stable state[16,18]. It was also lower
in the stable state in sputum from patients with frequent
exacerbations compared to those with infrequent exacer-
bations [19], suggesting that low concentrations of SLPI
increase the risk of developing an exacerbation. In addi-
tion it was lowest in those patients with the greatest neu-
trophilic inflammation in the stable state[20], and lower
in those who remained colonized in the stable state com-
pared to those who cleared their infection[18,21]. This
relation to infection has been confirmed in studies show-
ing that SLPI was also reduced in vaginal secretions in the
presence of bacterial infection [22].
In general, SLPI and NE concentration appear to be
inversely related in sputum in COPD and CB[23] but the
reason for this relationship in vivo is not understood. The
genetics of patients with early-onset COPD have been
investigated and no mutations, deletions or disease-asso-
ciated polymorphisms in the SLPI gene have been
described[24]. In our studies over 20 years, we have not
identified any patients with an absence of SLPI in sputum.
Therefore at present the concept that a primary deficiency
of SLPI initiates inflammation or infection is not well sup-
ported by the available data.
A number of studies have described an inverse relation-
ship between SLPI and NE in vitro using tissues ranging
from primary nasal and bronchial epithelial cells, through
a variety of cell lines, to isolated tracheal submucosal
glands [25-28]. Since cell culture supernatant from cells
exposed to NE has a lower concentration of SLPI protein
than supernatant from cells not exposed to NE, neu-
trophilic inflammation may directly predispose to low
SLPI in vivo. Previous in vitro work also included measure-
ment of SLPI gene expression in cells exposed to NE and
high levels were found to increase gene expression [26-
29]. The fall in protein must therefore relate to alterations
in post-transcriptional events. Immunohistochemical
studies of primary nasal epithelial cells showed greater
SLPI protein in cells treated with NE than those not
treated, suggesting failure of secretion or redistribution of
the protein rather than failure of synthesis[28]. Studies of
NE-treated cells lysed using a detergent-based solution
after removal of media demonstrated that the SLPI not
found in cell culture media was in the cell lysate [27].
One mechanism that might explain the NE-induced redis-
tribution of SLPI protein hinges on the positive charge of
the NE molecule, which may enable it to associate with
cell membranes [30]. Once associated with epithelial cell
membranes, it could bind SLPI, although not as efficiently
as in free solution[31], and would hence remove SLPI
from cell supernatant. The known structures of NE[32]
and SLPI[33] suggest that charged residues may remain
exposed on the outside of each molecule when complexed
with each other, so the NE-SLPI complex is likely to have
a more potent positive charge and therefore is more likely
than SLPI alone to associate with cell membranes and
negatively-charged proteins.
Other possible mechanisms include failure to secrete, or
binding of SLPI to other cell surface proteins exposed by
NE. For example, SLPI has been shown to bind specifically
to annexin II[34] and to scramblase[35], and these may
potentially be upregulated or exposed in the presence of
proteinases. It is known that there is a receptor specific for
the complex of NE and α1 antitrypsin (α1 AT) [36], and
therefore it is also possible that the SLPI-NE complex
binds to a specific receptor. Finally, there may be a mech-
anism to import SLPI actively into cells. Studies with neu-
trophils[37], megakaryocytes and platelets[38] show SLPI
inside cells, and a recent study indicated that macro-
phages can import exogenous SLPI into both the cyto-
plasm and nucleus[12].
In the present study, we have investigated the hypothesis
that charge-related association of the SLPI-NE complex
with cell membranes is the primary mechanism reducing
SLPI concentration in cell culture supernatants from SLPI
producing lung epithelial cells in the presence of NE. We
have conducted experiments investigating the nature of
the effect of NE on SLPI protein levels in cell culture super-
natant, and pursued preliminary studies into the localiza-
tion of SLPI in these cells when exposed to NE.
Methods
Proteinases and inhibitors
NE was purified from empyema fluid using the method of
Martodam et al[39]. Absence of endotoxin contamination
was confirmed with the Limulus amoebocyte assay (E-
TOXATE, Sigma, UK). Activity of NE was measured usingRespiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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the synthetic chromogenic substrate N-succinyl-(ala)3-p-
nitroanilide (Sigma, UK). Cathepsin G (CG) was similarly
obtained from empyema fluid and activity was measured
using N-succinyl-phe-pro-phe-p-nitroanilide (Bachem,
UK). Porcine pancreatic elastase (PPE) was obtained from
Sigma and the activity was measured using N-succinyl-
(ala)3-p-nitroanilide. Trypsin was cell culture grade (Invit-
rogen) and activity was measured using N-benzoyl-L-
arginine ethyl ester hydrochloride (BAEE) (Sigma).
Human mast cell chymase and tryptase were obtained
from Elastin Products Co. and activity was measured
using N-succinyl-val-pro-phe-p-nitroanilide and Z-gly-
pro-arg-p-nitroanilide respectively (both from Bachem).
ZD0892, a small synthetic peptidyl trifluoromethylketone
NE inhibitor with an affinity for NE similar to that of
SLPI[40], was a gift from Zeneca Pharmaceuticals (Wilm-
ington, USA) and inhibitory function was measured
against a known amount of active NE using N-succinyl-
(ala)3-p-nitroanilide. Recombinant human SLPI (rhSLPI)
was a gift from Amgen and the concentration was con-
firmed using the SLPI ELISA (see below). Inhibitory activ-
ity was determined as for ZD0892.
Measurement of SLPI and total protein
SLPI concentration was measured using the R&D Systems
ELISA, a sandwich ELISA consisting of a mouse mono-
clonal antibody for capture and a horseradish peroxidase-
conjugated polyclonal antibody for detection. Total pro-
tein was measured in microplates using the Bio-Rad assay
(Bio-Rad, USA). The ELISA was validated using mixtures
of SLPI and NE or CG in varying proportions to ensure
that the proteinases did not interfere with quantification
of SLPI. Briefly, recombinant human SLPI supplied as
standard in the ELISA kit was mixed at varying molar
ratios with NE and CG, incubated at 37°C for 30 minutes
and the amount of SLPI recoverable was measured using
the ELISA.
Cell culture
A549 cells, a lung epithelial cell line derived from lung
carcinoma, were obtained from the ECACC and cultured
in 50/50 F10/DMEM (both from Gibco, UK) with 10%
fetal calf serum (FCS) (Gibco). HepG2 cells, a liver epithe-
lial cell line derived from liver carcinoma, were obtained
from the ATCC. They were cultured in DMEM containing
10% FCS, antibiotic antimycotic solution, 150 mmol L-
glutamine and MEM non-essential amino acids (all from
Sigma). Primary human bronchial epithelial cells (PBEC)
were obtained from Cambrex (UK) and cultured in the
same supplier's recommended basal media with growth
supplements according to their instructions. Experiments
were carried out with cells between passage 3 and 8, using
basal media only.
Most experiments were performed on A549 cells and
selected experiments were repeated on PBEC or HepG2
cells in standard submerged monolayer culture. All exper-
iments were performed in at least triplicate wells, and
results are expressed as mean ± standard error of the mean
(SEM) of at least 3 experiments. Cells were cultured to
confluence in T75 or T25 flasks (Gibco) and plated out
into 12 or 24 well plates (Gibco). Once confluent, the
media were changed to serum free media (SFM) (50/50
F10/DMEM for A549 cells, DMEM alone for HepG2 cells
and basal media without additives for PBEC). A549 cells
and HepG2 cells were cultured in SFM for a further 24 h
before experiments were performed. After treatment with
the experimental conditions, supernatants were aspirated
and stored at -70°C for later analysis for SLPI and protein
concentrations. Cells were rinsed with PBS and harvested
using trypsin to detach them and viability was assessed
where appropriate using trypan blue exclusion. Statistical




A dose response experiment was undertaken to examine
the relationship of NE concentration to the reduction of
SLPI concentration in cell culture supernatants. The initial
concentration of SLPI in the cell supernatants was not
known at the outset of an experiment. Preliminary exper-
imental data showed that the typical concentration of
SLPI in supernatants of A549 cells after 24 h culture in
SFM was between 0.5 and 2 nM (5–23.4 ng/ml). Cells
were therefore incubated in SFM alone as control, or SFM
containing NE from 0.5 to 5 nM. Initial experiments also
included a control consisting of the buffer used to sus-
pend the NE, in SFM at the same concentration as the
highest concentration of NE used. Dose response experi-
ments were repeated with CG and using PBEC with both
proteinases.
2. Effect of other proteinases
Proteinases such as PPE have, like NE, been shown to
increase SLPI expression[29], although the effect on pro-
tein secretion has not been reported. PPE (which does not
bind SLPI), human mast cell chymase, trypsin and human
mast cell tryptase (which bind SLPI with varying affinity
but do not carry a high positive charge) were used to
assess whether the degree of binding to SLPI by the protei-
nase or its ability to associate with cell membranes by
charge would modify the ability of the proteinase to
reduce SLPI in the supernatant. The effect on SLPI secre-
tion was compared for PPE, trypsin, chymase, tryptase and
CG by incubating cells with varying concentrations of
each proteinase for 24 h.Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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3. Time course
The hypothesis of binding of the NE-SLPI complex to cell
membranes because of positive charge suggested that
addition of NE to conditioned media would cause
removal of SLPI that had already been secreted. Confluent
PBEC were cultured for 24 h in SFM and at the end of this
period an aliquot was removed for baseline analysis and
replaced with either SFM or NE at a concentration suffi-
cient to achieve 10 nM in each well. After gentle mixing of
the contents of the wells once with a 1 ml pipette, cells
were incubated for a further 24 h and aliquots of 25 μl
were taken at various time points within this period and
stored at -70°C for analysis by ELISA. Similar experiments
were repeated on A549 cells using both NE and CG, and
with 1 nM rhSLPI in DMEM added to HepG2 cells fol-
lowed by NE or SFM control. HepG2 cells were used as a
control cell line that does not express or secrete SLPI, to
demonstrate the effect of proteinases on SLPI concentra-
tion without any possibility of secreted SLPI contaminat-
ing the results.
4. Effect of a synthetic NE inhibitor
Addition of NE inhibitors to culture media containing NE
has been shown to abrogate the fall in SLPI protein[27]. If
binding of NE to SLPI is important in the mechanism of
the fall in SLPI protein, then the timing of the addition of
the inhibitor will be equally important. NE was incubated
for 30 min at 37°C with a tenfold excess of ZD0892. The
mixture of NE and ZD0892 was added to the supernatant
of A549 cells that had been serum-starved for 24 h, to
achieve a final concentration of 10 nM NE and 100 nM
ZD0892. This was compared with NE 10 nM added 10
minutes prior to the addition of 100 nM ZD0892, and
ZD0892 100 nM added 10 minutes prior to the addition
of NE 10 nM. Control cells were treated with NE 10 nM
alone, ZD0892 100 nM alone, or SFM alone. All mixtures
were incubated for a further 10 minutes and the superna-
tants were then aspirated and stored at -70°C for analysis
by ELISA.
5. Localization of SLPI in cell culture system
Given that many proteins associate non-specifically with
charged surfaces such as cell culture plastic, we speculated
that the NE-SLPI complex may associate more with cell
culture materials than SLPI alone. This was tested by com-
paring the concentration of SLPI in solutions added to
empty tissue culture plates with the concentration of SLPI
in solutions added to wells containing confluent cells,
with and without NE. SLPI was added to SFM to achieve a
concentration of 1 nM, and the solution was incubated in
12 well plates for 10 minutes, a baseline aliquot was taken
for measurement of SLPI and replaced with SFM or NE to
achieve a final enzyme concentration of 10 nM. After a
further period of incubation the contents of the wells were
harvested for measurement of SLPI concentration. In
order to block the effect of non-specific binding, both 12
well plates containing cells and 12 well plates without
cells were also incubated with media containing 1% w/v
human serum albumin (HSA) and SLPI at 1 nM. The effect
of 10 nM NE was assessed as before in both sets of plates.
Plates were also coated with HSA prior to addition of cells,
and the above experiments were repeated using plates
with or without A549 cells. Finally in cell-free conditions,
the effect of 1% Tween 20 (polyoxyethylene sorbitan
monolaurate, Sigma) was assessed in the same way.
6. Two compartment model
SLPI is secreted both basally and apically by cells in
vitro[41], and in vivo epithelial and glandular cells might
be exposed to NE release from neutrophils at both sites
during neutrophil migration. To examine whether this
may influence the secretion of SLPI, a two compartment
model was studied. Transwells (Transwell PET 0.4 μm
pore size 12 mm inserts, Corning Life Sciences) were
coated with human placental collagen (Sigma) at 50 μg/
ml and dried in air. A549 cells were added to the upper
compartment in 500 μl media, with 1.5 ml media in the
lower compartment. As soon as the cells appeared as a
confluent monolayer, media were replaced by SFM at the
same volumes. After a further 24 h incubation, reagents
were added to upper and lower compartments. Triplicate
wells received either SFM alone in both compartments or
NE 10 nM in one compartment with SFM in the other.
Supernatants were aspirated after a further 10 minutes
incubation, and stored at -70°C for later analysis for total
protein and SLPI concentration.
7. Theoretical modelling of the external charge of the complex 
between SLPI and proteinases
The modelling procedure involved the use of the X-ray
crystal structure of SLPI with chymotrypsin (structure file
kindly provided by Professor Wolfram Bode as described
previously[33]) as a template to construct analogous com-
plexes with other proteinases. X-ray crystal structures of
NE (PDB ID 1H1B; [42]), CG(PDB ID 1T32;[43]), trypsin
(PDB ID 1TX6;[44]), mast cell chymase (PDB ID
1T31;[43]) and mast cell tryptase (PDB ID 2BM2;[45])
were obtained from the Research Collaboratory for Struc-
tural Bioinformatics Protein Data Bank[46]http://
www.pdb.org. These structures were then superimposed
on the proteinase in the SLPI-proteinase complex using
SWISSPDB[47]http://www.expasy.org/spdbv/. The values
for the original proteinase (chymotrypsin) were then
deleted and the new complex saved. SLPI alone was
obtained by deleting chymotrypsin from the original
structure file. Electrostatic surfaces were generated using
SWISSPDB with values of -3.00, 2.00 and 8.00 for the red,
white and blue extremes of the spectrum.Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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Results
The ELISA confirmed SLPI concentration was fully recov-
erable at the range of concentrations of NE and CG used
in these experiments. However at very high molar ratios of
proteinase to inhibitor (> 100:1), there was a fall in quan-
tification which was attributed to the effects of unopposed
proteinase activity on the antibody used in the ELISA (Fig-
ure 1).
1. Dose-dependent effect of NE on SLPI in A549 
supernatants
NE at the concentrations used in these experiments did
not affect cell viability (by trypan blue exclusion, data not
shown). The concentration of SLPI after 24 h showed a
dose related fall with NE treatment from 1.36 ± 0.37 nM
at 0.5 nM to 0.20 ± 0.14 nM at 5 nM, whilst media control
contained 1.63 ± 0.31 nM (p = 0.006, one way ANOVA)
(Figure 2). Similar results were obtained when the experi-
ments were repeated with A549 cells using CG and with
PBEC using NE (data not shown).
Using a dose range from 0–2.5 nM NE, a linear relation-
ship was seen between the difference in SLPI concentra-
tion between treated and control cells, and the amount of
NE (Figure 3). This relationship suggests about 1.4 mole-
cules of NE are required to remove 1 molecule of SLPI
from cell culture media.
2. Effect of other proteinases
At high concentrations of proteinases, all cells detached
from the wells although cell viability was not affected dur-
ing the duration of the experiment as assessed by trypan
blue exclusion (data not shown). At these higher protein-
ase concentrations, SLPI concentration fell sharply. CG
caused a dose-dependent fall in SLPI concentration (79.9
± 8.2% of control values (p < 0.05) at 1 nM, 4.7 ± 4.3%,
0.02 ± 0.0% and 0.07 ± 0.1%, (p < 0.001) at 10 nM, 100
Validation of the ELISA for measuring SLPI with proteinases Figure 1
Validation of the ELISA for measuring SLPI with proteinases. Recombinant human SLPI was mixed with varying con-
centrations of NE and assayed by ELISA to assess the recovery of SLPI in complex with the proteinase and in the presence of 
excess proteinase. The molar ratio of proteinase to SLPI is given along the x axis, and the percentage of SLPI recovered is 
shown on the y axis. The figure shows the results obtained with NE, CG, PPE and trypsin. The ELISA was affected by a large 
molar excess of proteinase, but not at the molar ratios relevant to this paper (< 10:1).Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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nM and 1000 nM respectively), but had no effect at 0.1
nM (96.2 ± 0.8% control) while SLPI concentration fell
significantly only at high concentrations for PPE (9.0 ±
3.5% at 100 nM, 2.6 ± 1.3% at 1000 nM, p < 0.005) and
trypsin (4.5 ± 0.8% at 1000 nM, p < 0.005), at which cell
morphology was affected. Mast cell chymase caused a sig-
nificant reduction in SLPI secretion at concentrations
from 10–100 nM. This was associated with a marked
change in cell morphology: loss of cell-cell contact but no
detachment. At lower concentrations, with normal cell
morphology, there was no effect on SLPI secretion. Mast
cell tryptase did not affect either SLPI concentration or cell
morphology at any dose (Figure 4).
3. Time course of the effect of NE
Several groups have demonstrated that the presence of NE
reduces the amount of SLPI in cell supernatants after peri-
ods of culture ranging from 1 h to 48 h[26,27]. When NE
was added to wells containing A549 cells following 24
hours incubation (therefore containing substantial
amounts of SLPI), a rapid fall in SLPI concentration was
seen at the earliest time point tested (10 min). The results
were similar with PBEC (Figure 5a), A549 cells (data not
shown) and HepG2 cells (Fig 5b). CG also caused a
decrease in supernatant SLPI from media of A549 cells
within 10 min (control wells 102.36 ± 3.75% of baseline,
wells treated with CG 10 nM 1.50 ± 0.27% baseline at 10
minutes). Subsequent experiments using A549 cells
showed that NE already caused a detectable decrease in
SLPI within 2 min (data not shown).
4. Effect of synthetic NE inhibitor
ZD0892 alone did not affect SLPI concentration in A549
supernatants (99.12 ± 4.7% of media control). The con-
centration of SLPI in NE-treated wells fell to 12.05 ± 2%
of control values (p < 0.001 compared to media control).
When NE and ZD0892 were pre-incubated, the effect of
NE on SLPI was abrogated (100.2 ± 3.7% media control,
p < 0.005 compared to NE alone). Addition of NE after
ZD0892 caused some decrease in SLPI concentration (to
63.0 ± 8.5% of media control, p < 0.05 compared to
media control) but the fall in SLPI concentration was less
Effect of neutrophil elastase (NE) on SLPI in supernatants from cultured A549 cells Figure 2
Effect of neutrophil elastase (NE) on SLPI in supernatants from cultured A549 cells. A549 cells were cultured for 
24 h with NE at the concentrations shown, with an equivalent concentration of the buffer alone, or in a serum free media con-
trol. The y axis shows the average of the SLPI secreted in each condition as a percentage of the SLPI secreted by control cells 
(% SLPI release). Error bars represent standard error of the mean (SEM). N = 3–5 separate experiments for all except buffer 
control (N = 2). A dose-related reduction in SLPI supernatant concentration was seen with NE (statistically significant from 2.5 
nM) (p = 0.006, one way ANOVA).Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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than with NE alone (p < 0.05). Addition of NE before
ZD0892 caused a fall in SLPI concentration (to 28.7 ±
13.7% control, p < 0.05 compared to media control),
which was not significantly different from NE alone. The
difference between the results for NE and ZD0892 added
in either order was not statistically significant. These
experiments are summarised in Figure 6.
5. Attachment of SLPI to plastic surfaces
We next explored whether the loss of SLPI in the presence
of NE required the presence of cells, or whether it would
occur in cell-free conditions. We added SLPI to empty tis-
sue culture plate wells with or without NE. There was a
marked loss of SLPI from the empty tissue culture plates
as only about 1% of the expected amount was recovered
from control wells and therefore an additional effect of
NE could not be identified. Further investigation demon-
strated that there was a large loss of SLPI when diluted in
SFM in standard 20 ml polystyrene tubes, and a further
loss in tissue culture plates, which was attributed to
charge-related non-specific binding to plastic (data not
shown). This may have explained the observed decrease in
SLPI in cells treated with high concentrations of trypsin or
PPE that caused detachment, since this would have
exposed culture plastic which would be capable of bind-
ing the previously secreted SLPI, resulting in a fall in SLPI
concentration in the supernatant.
Use of polypropylene plates and siliconised glass culture
systems did not offer more than partial protection against
this loss of SLPI (data not shown) and cells did not grow
satisfactorily without a substrate on siliconised glass.
Addition of HSA 1% w/v to culture media, or coating of
tissue culture plates with HSA or human placental colla-
Relationship between NE and SLPI decrease in the supernatant of A549 cells Figure 3
Relationship between NE and SLPI decrease in the supernatant of A549 cells. The total NE-induced decrease in 
SLPI concentration, calculated from the experiment shown in Figure 2, was plotted against the concentration of NE used and a 
linear relationship found (Pearson correlation coefficient 0.846, p < 0.001).Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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gen prior to plating out cells, partially reduced the non-
specific loss of SLPI from culture media (data not shown).
Furthermore the presence of HSA in solution partially
inhibited the effect of NE in reducing SLPI concentration
in cell-free systems (Figure 7), and similarly in plates
coated with HSA prior to plating out cells (data not
shown). Addition of 1% Tween to cell-free systems com-
pletely prevented loss of SLPI when incubated without
NE, but did not prevent almost total loss of SLPI in the
presence of NE (data not shown).
6. Two compartment model
Supernatant from the upper compartments of Transwells
on which A549 cells were cultured contained about four-
teen times as much SLPI as the lower compartments. The
difference may be due to polarized secretion of SLPI, or
might be accounted for by SLPI binding to the plastic of
the cell culture plates in the lower compartment, which
had not been treated to prevent non-specific binding and
contained no cells. Addition of NE to the upper compart-
ment caused reduction in SLPI concentration to 10.6 ±
0.3% of control values, and in the lower compartment it
caused a reduction to 8.6 ± 1.9% of control. SLPI concen-
trations in the control-treated compartment were not
affected (Figure 8).
7. Theoretical modelling of SLPI in complex with 
proteinases
Figure 9 shows the SLPI molecule alone (Fig 9a) and SLPI-
proteinase complexes (Fig 9b–f). Using colour to indicate
charge (red for negative, blue for positive), it can be seen
that both NE and CG produced a highly positively-
charged complex with SLPI. Mast cell chymase and trypsin
varied in charge on the two aspects shown whereas mast
cell tryptase was highly negatively-charged on both
aspects. PPE was not modelled for this experiment
because it does not bind SLPI. The results suggest that SLPI
in complex with CG and NE would be predicted to associ-
Effect of other proteinases on SLPI concentration in A549 cells Figure 4
Effect of other proteinases on SLPI concentration in A549 cells. A549 cells were cultured with varying concentrations 
of each proteinase for 24 h. The concentration of SLPI, expressed as a percentage of the concentration in serum free media, is 
shown on the y axis with the SEM represented by error bars. P indicates that the cells exhibited morphological changes of par-
tial detachment, 'rounding up' and losing attachment to each other but remaining adherent to the culture plate, whilst D indi-
cates that the cells detached completely from the culture plate. The effect on SLPI concentration was only independent of cell 
morphology for CG. Values given are mean ± SEM for at least 3 experiments.Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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ate more with negatively-charged surfaces than either free
SLPI, or SLPI complexed with other proteinases, because
of the greater positive charge.
Discussion
The results from the present study show that both NE and
CG decrease SLPI released into culture supernatants from
lung epithelial cells. The dose response of the proteinases
was linear, and the effect was almost immediate. Experi-
ments using a synthetic NE inhibitor showed that when
the inhibitor was added together with NE, the NE-medi-
ated decrease in SLPI was completely prevented. In con-
trast, when the inhibitor was added after NE had been
applied to the cells it only partially prevented a reduction
in SLPI. Experiments using a Transwell model showed
that the effect of NE on SLPI required direct contact
between these molecules, suggesting that direct binding of
NE or CG to SLPI was involved.
Only the strongly cationic proteinases NE and CG were
able to reduce SLPI concentration at almost molar equiv-
alent doses. The other proteinases only caused reduction
in SLPI when used at concentrations sufficient to alter cell
morphology and/or cause detachment, which probably
leads to non-specific binding to the tissue culture plastic.
Theoretical modelling of surface charge supported the
concept that an NE-SLPI or CG-SLPI complex would have
a greater positive charge than SLPI alone or in complex
with the other proteinases studied. Therefore it seems
likely that the reduction in SLPI concentration in the pres-
ence of proteinases was mediated by charge-related bind-
ing to other structures.
Previous studies on the effect of NE on SLPI in vitro have
shown a decrease in SLPI concentration with a variety of
cells and tissues [25-27], but only two studies have
attempted to explore this further. The study by Marchand
et al[28] used immunohistochemistry to examine nasal
explanted epithelial tissue exposed to NE and found
greater signal than in the control tissues not exposed to
NE. The study by van Wetering et al[27] used PBEC and
again found a dose-dependent effect, present from a few
hours after exposure of cells to NE, which could be inhib-
ited by co-administration of an inhibitor (α1 AT). Analy-
Time course of the effect of NE on SLPI concentration Figure 5
Time course of the effect of NE on SLPI concentration. Figure 5a: PBEC were cultured in basal media for 24 h, and 
then an aliquot of media was removed as baseline and replaced with the same volume of media control or media containing NE 
at a concentration sufficient to achieve a concentration of 10 nM in the wells. Further aliquots were taken at the times shown, 
and SLPI concentration was measured by ELISA. The figure shows the results from 3 experiments. The y axis gives the concen-
tration of SLPI as % of the baseline value for triplicate wells treated with basal media or NE. (Error bars indicate SEM.) The 
concentration of SLPI fell at the earliest time point studied in wells treated with NE but remained stable in the media controls. 
Over 24 h the concentration in media controls rose in accordance with the steady state concentrations predicted, but 
remained low in NE-treated wells. At 24 h, some SLPI was present in the media of NE-treated cells but this was substantially 
lower than the media controls (p < 0.001 Wilcoxon signed ranks test). b: HepG2 cells were cultured in 12 well plates and, after 
rinsing with PBS, media containing 1 nM SLPI was added to the cells. After a few minutes equilibration, a baseline aliquot was 
removed and replaced with either media control or NE to achieve a final concentration of 10 nM. Further aliquots were taken 
at the time points shown. In the media controls it remained stable throughout, but the concentration in NE-treated wells fell 
significantly at 10 minutes and remained low thereafter (p < 0.001 Wilcoxon signed ranks test).Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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sis of cell lysates indicated that SLPI became cell-
associated in the presence of NE rather than in the culture
media, and hence suggested a block in secretion or redis-
tribution of the protein rather than an effect on synthesis.
These studies did not pursue more detailed analysis of the
relationship between NE and SLPI concentration and the
possible mechanism responsible for this relationship. In
addition, none of the studies in the literature has control-
led for non-specific binding of SLPI to tissue culture mate-
rials. Studies on the ability of SLPI to protect fibronectin
from degradation by NE showed that SLPI could associate
with this substrate through ionic interactions [48] and
examination of human lung tissue showed that SLPI was
associated with elastin fibres[49], again suggesting non-
specific binding. SLPI binds non-specifically to many
large molecules such as mucins[50] and DNA[51], how-
ever, to our knowledge no studies have examined whether
the NE-SLPI complex is more likely to associate with cells
or substrates than SLPI alone.
Our initial validation studies demonstrated that in the
presence of a molar excess of NE or CG, detection of SLPI
by ELISA was not affected. The studies described here did
not examine the possibility of cleavage or degradation of
SLPI by excess of proteinase, but even if this happened,
the cleavage products would appear to be detected fully by
the ELISA, suggesting that the monoclonal capture anti-
body recognises an epitope not affected by proteolysis,
and that the polyclonal detection antibody also recognises
preserved sites. Incubation with samples containing exces-
sive amounts of NE may however expose the capture anti-
body to proteolytic degradation, and this may be the
explanation for the fall in detection at high concentrations
of NE, rather than degradation of SLPI by NE. Since the
Timing of the addition of inhibitor to NE affects concentration of SLPI Figure 6
Timing of the addition of inhibitor to NE affects concentration of SLPI. The diagram shows the concentration of SLPI 
in the media of wells treated according to the conditions shown on the x axis. The concentration of SLPI is expressed as % of 
the concentration in control wells. * indicates significant difference from control wells, $ indicates significant difference from 
NE-treated wells. Values shown are mean ± SEM for 3 experiments. Prior incubation of NE with a tenfold excess of ZD0892 
completely abrogated the effect of NE on SLPI concentration. When NE and ZD0892 were added separately, there was a fall in 
SLPI concentration which was less pronounced than that seen with NE alone, but still significantly different from both media 
control and NE alone. Although the average fall was greater when NE was added before rather than after ZD0892, this differ-
ence was not statistically significant.Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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validation studies used recombinant rather than endog-
enous SLPI and were conducted in assay buffer rather than
conditioned cell culture media, it cannot be guaranteed
that the ELISA would perform as reliably in experimental
conditions. However in the published studies previously
mentioned, the same effect of dose-dependent reduction
of SLPI in the cell culture environment was shown by sys-
tems using a variety of different antibodies for detection
of SLPI, suggesting that the effect is real rather than a sys-
tematic measurement error. Possible effects on the ELISA
from complex formation or cleavage of SLPI therefore
cannot fully explain the complete loss of signal of SLPI in
the presence of cells treated with NE. Nevertheless, our
experiments do not conclusively demonstrate that SLPI
bound to cells in presence of NE is biologically active. Fur-
thermore, it needs to be noted that the difficulties in
avoiding non-specific binding of SLPI to the plastic com-
ponents of the cell culture system are not fully countered
in these studies. If the hypothesis that binding of SLPI to
NE causes adherence to cells by charge interactions is
valid, then the same mechanism could apply to any nega-
tively-charged surface, such as plastic cell culture compo-
nents which were also shown to bind free SLPI avidly. NE
did appear to increase non-specific binding of SLPI to
plastic, because when detergent was used as a blocking
agent, SLPI concentration fell only in the presence of NE
(suggesting that the higher ionic charge of the NE-SLPI
complex was able to overcome the concentration of deter-
gent used). The ELISA system contains strong buffering
agents that must be presumed to protect against loss of
free SLPI. The validation studies suggest that they are suf-
ficient to protect also against loss of the NE-SLPI complex.
However it cannot be presumed that there was not loss of
SLPI to plastic during the cell culture process, harvesting
of supernatant and storing of the samples prior to prepa-
ration of the ELISA, and that this loss of SLPI was not
enhanced in the presence of NE solely by increased bind-
ing to plastic rather than to cell membranes. Proof of the
concept of binding of SLPI to cells would require a differ-
ent experimental approach, and therefore the experiments
presented here cannot claim to prove that the effect is bio-
logical and relevant to the in vivo situation. The location
Protection by albumin against non-specific binding of SLPI to plastic Figure 7
Protection by albumin against non-specific binding of SLPI to plastic. The diagram shows the concentration of SLPI in 
SFM added to tissue culture plates without cells, before addition of NE or control (baseline) and 10 min afterwards. Parallel 
wells used SFM containing human serum albumin at 1 mg/ml. Data shown are the mean results from 3 experiments with SEM 
represented by the error bars. Without albumin, almost all the SLPI was lost regardless of whether NE was added. Albumin 
provided partial protection against loss of SLPI at baseline and after addition of NE.Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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of the lost SLPI protein remains uncertain, although pre-
liminary immunofluorescence studies in our laboratory
suggested at least in part that the SLPI does become inter-
nalised (data not shown). Further studies, using SLPI
bound to a fluorescent or radioactive label that does not
impede binding to NE, will be required to confirm this.
There is a likely biological relevance of the phenomenon
of free SLPI associating with cell membranes and extracel-
lular matrix proteins because this would allow the lung to
establish a protective antiproteinase coat over structures
that would be at most risk of damage by free NE. The
major function of NE is probably intracellular killing of
bacteria within the phagolysosome. Where neutrophils
are migrating through the lung, some local NE activity
(from a released azurophil granule or released from cell
membrane association) may possibly be beneficial to this
process. Free NE in lung secretions however is believed to
be uniformly deleterious. Where this occurs, it would be
neutralized to some extent by the presence of SLPI bound
to vulnerable structures. There may be some value in the
SLPI-NE complex associating with these structures. If the
NE-SLPI complex prevented further association of NE
with extracellular matrix substrates more effectively than
SLPI alone (because of its higher positive charge), it would
leave the free NE in epithelial lining fluid to be inactivated
by α1 AT, which the latter cannot do once NE is bound to
substrate[52]. There are no published data on the avidity
of binding of the NE-SLPI complex to cell membranes or
matrix substrates. However it is known that there is a
strong association between NE and neutrophil cell mem-
branes[30], and between SLPI and fibronectin[48], based
on the ionic strength or pH required to dissociate them.
The ionic charge of the NE-SLPI complex has never been
The effect of NE on SLPI concentration in media of cells grown on Transwells Figure 8
The effect of NE on SLPI concentration in media of cells grown on Transwells. The diagram shows the concentra-
tion of SLPI in each compartment of A549 cells grown in Transwells, relative to the concentration in control wells. Wells were 
treated with either 10 nM NE or serum free media (SFM) alone for 10 minutes, and the concentration of SLPI was then deter-
mined by ELISA. Upper and lower compartment results for the same well are adjacent; the solid bars indicate upper compart-
ments and the open bars indicate lower compartments. SFM/NE indicates that NE was applied to the lower compartment only 
whilst NE/SFM indicates that NE was applied to the upper compartment only. The concentration of SLPI in the NE-treated 
compartments fell significantly (p = 0.001 by independent t-test) from 100% to 10.6 ± 0.3% (NE added to upper compartment) 
and 8.6 ± 1.9% (NE added to lower compartment) whilst there was no difference in concentration of the paired SFM-treated 
compartments (99.9 ± 1.5% and 90.31 ± 7.8% of control wells respectively).Respiratory Research 2008, 9:60 http://respiratory-research.com/content/9/1/60
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measured, because the binding of these two strongly cati-
onic molecules is sufficiently reversible that standard elec-
trophoretic methods cause them to dissociate. It is also
unknown how stable the complex would be when mem-
brane-bound. It is possible that membrane-bound com-
plex might be able to dissociate, or be passively
internalised during membrane cycling, or actively inter-
nalised by endocytosis or phagocytosis, probably requir-
ing a specific receptor. Internalisation of the complex
might generate biological responses central to lung
inflammation. Further studies will clearly be required to
explore these possibilities.
Conclusion
In summary, the experiments described in this paper sup-
port the hypothesis that the association of SLPI in com-
plex with NE to negatively-charged structures leads to its
removal from cell culture media, and that this effect is a
passive biochemical process, probably dependent on
charge. It is likely that this effect occurs with cell mem-
branes as well as non-biological components, but this has
yet to be confirmed. Future experiments should include
measures to counter the ability of SLPI to bind non-specif-
ically to a variety of structures, particularly in the presence
of NE or CG.
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